Quarterly Financial Results - Contains consolidated financial statements for the six-month period ending June 30, 2026, including income statements, balance sheets, cash flow statements, and statements of equity for comparison with prior year periods (H1 2025) Debt Securities Information - Discloses multiple senior notes outstanding with various maturity dates (2027-2031) and interest rates,…

Our analysis rates this filing CAUTIOUS. AbbVie presents an elevated but manageable risk profile. The primary concerns center on execution risk from two significant acquisitions completed in H1 2026 and a substantial debt refinancing schedule concentrated in 2027-2029. The integration of Apogee and…

Concern level: ELEVATED (5.8/10). Key factors: Recent acquisitions of Apogee Therapeutics and Nimble Therapeutics introduce material integration execution risk and potential goodwill impairment exposure if synergy targets are not achieved; Concentrated debt maturity schedule with $7.5B due 2027-2029 creates refinancing risk in elevated interest rate environment, potentially increasing debt…

Notable risk changes: Two significant acquisitions completed in H1 2026 (Apogee Therapeutics and Nimble Therapeutics) - introduces material integration risk and potential for goodwill impairment if synergies not realized; Substantial debt maturity schedule with $2.625B due 2028 and $2.125B due 2029 - refinancing risk in higher rate environment not quantified in current filing; Multiple collaborative arrangements…

The model predicts ABBV will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.